Suppression of galectin-3 expression enhances apoptosis and chemosensitivity in liver fluke-associated cholangiocarcinoma

Cancer Science

Volumn 100, Issue 11, 2009, Pages 2077-2084

  Wongkham, Sopit ^a,b   Junking, Mutita ^a,b   Wongkham, Chaisiri ^a,b   Sripa, Banchob ^a,b   Chur in, Siri ^a,b   Araki, Norie ^c  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; GALECTIN 3; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; FASCIOLA HEPATICA; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; ULTRAVIOLET IRRADIATION;

APOPTOSIS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; FASCIOLIASIS; GALECTIN 3; HUMANS; RNA INTERFERENCE;

EID: 71049141299     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01304.x     Document Type: Article

References (34)

1. Vatanasapt V, Tangvoraphonkchai V, Titapant V, Pipitgool V, Viriyapap D, Sriamporn S. A high incidence of liver cancer in Khon Kaen Province, Thailand. Southeast Asian J Trop Med Public Health 1990, 21:489-94.
2. Haswell-Elkins MR, Mairiang E, Mairiang P. Cross-sectional study of Opisthorchis viverrini infection and cholangiocarcinoma in communities within a high-risk area in northeast Thailand. Int J Cancer 1994, 59:505-9.
3. Thongprasert S. The role of chemotherapy in cholangiocarcinoma. Ann Oncol 2005, 16(Suppl 2):93-6.
4. Junking M, Wongkham C, Sripa B, Sawanyawisuth K, Araki N, Wongkham S. Decreased expression of galectin-3 is associated with metastatic potential of liver fluke-associated cholangiocarcinoma. Eur J Cancer 2008, 44:619-26.
5. Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994, 269:20807-10.
6. Hirabayashi J, Kasai K. The family of metazoan metal-independent beta-galactoside-binding lectins: structure, function and molecular evolution. Glycobiology 1993, 3(4):297-304.
7. Hughes RC. Galectins as modulators of cell adhesion. Biochimie 2001, 83:667-76.
8. Yang RY, Liu FT. Galectins in cell growth and apoptosis. Cell Mol Life Sci 2003, 60:267-76.
9. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 1997, 57(23):5272-6.
10. Kim HR, Lin HM, Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 1999, 59(16):4148-54.
11. Lin HM, Moon BK, Yu F, Kim HR. Galectin-3 mediates genistein-induced G(2)/M arrest and inhibits apoptosis. Carcinogenesis 2000, 21:1941-5.
12. Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A 1996, 93(13):6737-42.
13. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 2002, 277(9):6852-7.
14. Hsu DK, Yang RY, Pan Z. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol 2000, 156(3):1073-83.
15. Sripa B, Leungwattanawanit S, Nitta T. Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). World J Gastroenterol 2005, 11(22):3392-7.
16. Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002, 26:199-213.
17. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227(5259):680-5.
18. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979, 76(9):4350-4.
19. Skehan P, Storeng R, Scudiero D. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990, 82(13):1107-12.
20. Lin CI, Whang EE, Abramson MA. Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. Biochem Biophys Res Commun 2009, 379:626-31.
21. Shi Y, He B, Kuchenbecker KM. Inhibition of Wnt-2 and galectin-3 synergistically destabilizes beta-catenin and induces apoptosis in human colorectal cancer cells. Int J Cancer 2007, 121:1175-81.
22. Tepsiri N, Chaturat L, Sripa B. Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J Gastroenterol 2005, 11(18):2748-53.
23. Hoyer KK, Pang M, Gui D. An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am J Pathol 2004, 164(3):893-902.
24. Takenaka Y, Fukumori T, Yoshii T. Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol 2004, 24:4395-406.
25. Yu F, Finley RL, Raz A, Kim HR. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem 2002, 277:15819-27.
26. Fukumori T, Oka N, Takenaka Y. Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res 2006, 66(6):3114-9.
27. Fukumori T, Takenaka Y, Yoshii T. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res 2003, 63(23):8302-11.
28. Matarrese P, Tinari N, Semeraro ML, Natoli C, Iacobelli S, Malorni W. Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. FEBS Lett 2000, 473:311-5.
29. Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004, 64(10):3365-70.
30. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003, 63(17):5198-202.
31. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002, 2:243-7.
32. Rabinovich GA, Cumashi A, Bianco GA. Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology 2006, 16(3):210-20.
33. Johnson KD, Glinskii OV, Mossine VV. Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. Neoplasia (New York, NY) 2007, 9(8):662-70.
34. Chauhan D, Li G, Podar K. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res 2005, 65(18):8350-8.